Pharming Group Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Pharming Group N.V. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue297.20245.32205.62198.87212.17169.02135.13
Cost of Revenue35.4025.21-17.5621.14-23.5421.3622.18
Gross Profit261.80220.10188.06177.73188.64147.67112.95
Operating Expenses
Research & Development83.1568.9152.5065.3838.5028.3728.88
Selling, General & Administrative184.4387.50131.8090.9775.7049.8740.95
Operating Expenses265.40242.39184.30153.73114.2086.7674.96
Operating Income-3.59-22.293.7624.0074.4460.9137.99
Other Income/Expense
Interest Income4.863.660.090.050.721.010.02
Interest Expense-8.745.965.36-6.09-5.9411.9214.31
Other Income/Expense3.7812.71-12.26-0.09-2.23-3.32-1.64
Income
Income Before Tax-8.49-12.0114.9923.0844.0946.680.86
Income Tax Expense3.35-1.461.317.086.3510.48-24.14
Net Income-11.84-10.5513.7216.0037.7336.2024.99
Net Income - Continuous Operations-11.84-10.5513.6716.000.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA3.229.8824.2230.3950.2763.7721.73
EBIT-3.59-6.0511.0424.0041.9558.6015.17
Depreciation & Amortization6.829.16-3.026.39-6.050.980.62
Earnings Per Share
Basic EPS-----1.00-
Diluted EPS-----1.00-
Basic Shares Outstanding671.3567.46648.68642.01636.2762.6360.66
Diluted Shares Outstanding671.3567.46686.20701.15628.7567.3565.35